|
October
23,
2002 Issue 127
From
The Editor's Desk:
 I
recently spoke to over 300 pharmacists about diabetes and when I asked
them if they knew a diabetes educator in their area, only 4 could answer
positively. If you are an educator, find a pharmacist in your area who
can help you with drug therapy questions. If you are a pharmacist find
an educator who can help you help your diabetes patients.
Diabetes
month is coming up soon and a lot of you have asked for a handout you
could give to clients who may be at risk of diabetes. I think Diabetes,
the Silent Killer, is the perfect handout. Click
here to view.
Over
100 Medical Professionals requested the Free A1c Kits, request yours
now! Limited quantities
available. Diabetes In Control is partnering with Biosafe Kids to
distribute free and low-cost A1c tests to underserved members of
the diabetes population through medical professionals.
Check out this week’s Tools
for your Practice.
I
have been trying out some new interactive software from dbaza.
This is a program that parents and kids can use together on the computer
to learn about diabetes and self care. I will have a complete review
including comments from families next week.
Eric
S. Freedland, MD
brings
us the final installment of his highly read series:
Why Focusing On Intensive
Glucose Control
With Drugs Alone Is Counterproductive--Potentially effective, available
interventions.
If
you want to know why using the most aggressive treatments upon
diagnosis of Type 1 diabetes can make a difference in the life of
your patients check out Items #1
and #2
We
have just returned from the National Community Pharmacist Association
Meeting in Nashville and will report on some new initiatives for
pharmacists and diabetes next week.
Consider
making Diabetes in Control Your home page. (IE Users)
Dave Joffe, Editor-in-Chief
Steve Freed, Publisher
News
Flash - News Flash
UPDATE:
FDA
Approves New Hypertension Drug. Inspra®
Pharmacia Corp. said on
Monday that it has received approval from the FDA to market its hypertension
drug eplerenone (Inspra), which is expected to work in a broad range of
patients.
Eplerenone
is the first drug designed to selectively block the hormone aldosterone, a
key component within the renin angiotensin aldosterone system (RAAS), which
has been shown in pre-clinical and clinical studies to play a role in the
regulation of the cardiovascular system.
1.
Optimize Control of Type 1 Diabetes From Diagnosis*
Click
Here
2.
Using Insulin Pumps at Time of Diagnosis for Type 1 Diabetes
Click
Here
3.
Waist Size Not BMI is Key for Determining Risk for CVD and Diabetes
Click
Here
4.
A New Two-Step Screening Protocol for Type 2 Diabetes*
Click
Here
5.
Oral Insulin Spray Reported Safe, Effective Replacement for
Injected Insulin
Click
Here
6.
Equal Survey Reveals: Americans Concerned About Developing Diabetes
Click
Here
7.
Diabetes Substantially Increases the Risk of UTI
Click
Here
8.
Age and the Burden of Death Attributable to Diabetes in the United
States.
Click
Here
9.
Discovery Health Channel Features Three Special Diabetes Programs This
November*
Click
Here
10.
Fat Children Outweigh Fat Adults
Click
Here
11.
Sharps, Waste Management, BD Launch Needle Disposal Program
Click
Here
12.
Phytoestrogen Use Reduces Heart Disease Risk in Women With Type 2
Diabetes*
Click
Here
13.
Gene Type Forecasts Diabetic Nerve Damage
Click
Here
14.
VHA Launches Diabetes Education Campaign Aimed at Minority Children
Click
Here
15.
Autonomic Defect At Root Of Low Glucagon Response In Type 1 Diabetes
Click
Here
Product
Update
A1cNow
is Less Than 9 Dollars!
Now
less than 9 dollars for the first and only NGSP A1c test that is
instant and disposable.
For more info on how you can now use it in your office practice
Click Here
75%
of patients with diabetes are not getting the recommended A1c testing.
Packed
with Many Valuable Features... you'd
expect to pay over $2000.00 for a Website
Like This...
See
Examples, and Learn More.....>Click
Here
|
SUBSCRIBE |
|
|
|
NEWS
FLASH
!!!
|
|
 Drug
Card
Program
for
Seniors
Raises
Drug
Costs
Firms,
Agency
Clash
Over
Pricing
Law.
A
widely
advertised
discount
drug
program
for
Medicare
patients
abruptly
raised
its
prices
for
thousands
of
users
this
week.
Drug
giants
Bristol-Myers
Squibb
Co.
and
GlaxoSmithKline
PLC,
two
of
the
seven
pharmaceutical
companies
that
created
the
program
to
ward
off
criticism
they
were
charging
seniors
and
disabled
people
too
much
for
drugs,
said
yesterday
that
they
were
forced
to
reduce
some
of
their
discounts
in
the
Together
Rx
program
to
comply
with
a
federal
drug-pricing
law.
Read
More...
|
|
Eric S.
Freedland, MD, 
Optimize Control of Type 1 Diabetes From Diagnosis* 
